The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.

Dermatology Clinical Trials Unit

Mary Tabacchi, Clinical Research Coordinator
Phone: 314-362-8171 Fax: 314-362-6080

Nancy Bodet, Research Nurse Coordinator
Phone: 314-273-1376 Fax: 314-362-6080

Milan Anadkat, MD, Director, Clinical Trials Unit 

Currently Enrolling Trials

Dr. Milan Anadkat

Placebo-Controlled Study Efficacy and Safety of BIIB059 (CD-123 antagonist) in Subjects with Active Cutaneous Lupus Erythematosus

Randomized, double-blind, multicenter study assessing short (16 weeks) and long-tem efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous Secukinumab dose regimens in adult patients with moderate to severe Hidradenitis Suppurativa

Phase 1, Open-Label, Dose Escalation Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy Study of Topically Administered LUT014 (BRAF agonist) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions

Dr. Becca Chibnall

PROSE Study: Prospective Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis

Randomized, Double-Blind, Placebo-controlled study of Efficacy, Safety, and Tolerability of Serlopitant (nuerokinin inhibitor) for the treatment of Chronic Pruritus of Unknown Origin

Dr. Lynn Cornelius

PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Dr. Heather Jones

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum (Cannabanoid) in Dermatomyositis

Dr. Ann Martin

Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of BTX 1503 in Patients with Moderate to Severe Acne Vulgaris

A Multicenter, Randomized, Double-Blind, Secukinumab-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis

Dr. Amy Musiek

SOLAR: A Phase 2, Randomized, Open-Label, Parallel-Group, Active Comparator, Multicenter Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis

A Double-Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL)

Phase 3, Multicenter, Randomized, Placebo-Controlled Study to Determine the Efficacy of Topical SGX 301 and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma